EGFR Inhibition Strongly Modulates the Tumour Immune Microenvironment in EGFR-Driven Non-Small-Cell Lung Cancer
出版年份 2022 全文链接
标题
EGFR Inhibition Strongly Modulates the Tumour Immune Microenvironment in EGFR-Driven Non-Small-Cell Lung Cancer
作者
关键词
-
出版物
Cancers
Volume 14, Issue 16, Pages 3943
出版商
MDPI AG
发表日期
2022-08-17
DOI
10.3390/cancers14163943
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Granzymes: The Molecular Executors of Immune-Mediated Cytotoxicity
- (2022) Zachary L. Z. Hay et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Harnessing Natural Killer Cells in Non-Small Cell Lung Cancer
- (2022) Éilis Russell et al. Cells
- Downregulation of TPX2 impairs the antitumor activity of CD8+ T cells in hepatocellular carcinoma
- (2022) Xiaochen Wang et al. Cell Death & Disease
- IRF1 regulates the progression of colorectal cancer via interferon‑induced proteins
- (2021) Xiaohui Xu et al. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I
- (2021) Johannes Brägelmann et al. Nature Communications
- NK Cell Therapy: A Rising Star in Cancer Treatment
- (2021) Nawen Du et al. Cancers
- Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR-mutated non–small cell lung cancer
- (2020) Eri Sugiyama et al. Science Immunology
- CDK1, CCNB1, and CCNB2 are Prognostic Biomarkers and Correlated with Immune Infiltration in Hepatocellular Carcinoma
- (2020) Yiping Zou et al. MEDICAL SCIENCE MONITOR
- Overexpression of TPX2 predicts poor clinical outcome and is associated with immune infiltration in hepatic cell cancer
- (2020) Hongjun Zhu et al. MEDICINE
- T cell signaling and Treg dysfunction correlate to disease kinetics in IL-2Rα-KO autoimmune mice
- (2020) Genevieve N. Mullins et al. Scientific Reports
- Targeting DDR2 enhances tumor response to anti–PD-1 immunotherapy
- (2019) Megan M. Tu et al. Science Advances
- Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors
- (2019) Deborah Ayeni et al. Journal for ImmunoTherapy of Cancer
- Impact of EGFR-TKIs combined with PD-L1 antibody on the lung tissue of EGFR-driven tumor-bearing mice
- (2019) Yijun Jia et al. LUNG CANCER
- Combined VEGF and PD-L1 blockade displays synergistic treatment effects in an autochthonous mouse model of small cell lung cancer
- (2018) Lydia Meder et al. CANCER RESEARCH
- Nivolumab Plus Erlotinib in Patients With EGFR -Mutant Advanced NSCLC
- (2018) Scott Gettinger et al. Journal of Thoracic Oncology
- Reversal of indoleamine 2,3-dioxygenase–mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme
- (2018) Todd A Triplett et al. NATURE BIOTECHNOLOGY
- Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung Carcinoma
- (2018) Chee Khoon Lee et al. JAMA Oncology
- Preclinical studies reveal that LSD1 inhibition results in tumor growth arrest in lung adenocarcinoma independently of driver mutations
- (2018) Iris F Macheleidt et al. Molecular Oncology
- The TNF Family of Ligands and Receptors: Communication Modules in the Immune System and Beyond
- (2018) Catherine Dostert et al. PHYSIOLOGICAL REVIEWS
- Checkpoint Inhibitors in Metastatic EGFR- Mutated Non–Small Cell Lung Cancer—A Meta-Analysis
- (2017) Chee Khoon Lee et al. Journal of Thoracic Oncology
- Implications of the tumor immune microenvironment for staging and therapeutics
- (2017) Janis M Taube et al. MODERN PATHOLOGY
- Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
- (2017) Angel Garcia-Diaz et al. Cell Reports
- Cancer treatment and survivorship statistics, 2016
- (2016) Kimberly D. Miller et al. CA-A CANCER JOURNAL FOR CLINICIANS
- EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis
- (2016) J. F. Gainor et al. CLINICAL CANCER RESEARCH
- Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses
- (2016) Kelly D Moynihan et al. NATURE MEDICINE
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Global cancer statistics, 2012
- (2015) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation
- (2015) Nan Chen et al. Journal of Thoracic Oncology
- Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
- (2015) Kenneth S Thress et al. NATURE MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune evasion in cancer: Mechanistic basis and therapeutic strategies
- (2015) Dass S. Vinay et al. SEMINARS IN CANCER BIOLOGY
- CCL21 and IFNγ Recruit and Activate Tumor Specific T cells in 3D Scaffold Model of Breast Cancer
- (2014) Vy Phan-Lai et al. Anti-Cancer Agents in Medicinal Chemistry
- AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
- (2014) D. A. E. Cross et al. Cancer Discovery
- Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor–Resistant Disease
- (2013) Kadoaki Ohashi et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical targeting of the TNF and TNFR superfamilies
- (2013) Michael Croft et al. NATURE REVIEWS DRUG DISCOVERY
- Overview of Complement Activation and Regulation
- (2013) Marina Noris et al. SEMINARS IN NEPHROLOGY
- Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
- (2013) E. A. Akbay et al. Cancer Discovery
- Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
- (2009) M. Ahmadzadeh et al. BLOOD
- The significance of OX40 and OX40L to T-cell biology and immune disease
- (2009) Michael Croft et al. IMMUNOLOGICAL REVIEWS
- Locally Produced Complement Fragments C5a and C3a Provide Both Costimulatory and Survival Signals to Naive CD4+ T Cells
- (2008) Michael G. Strainic et al. IMMUNITY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now